Selectis HealthGBCS -2.78%45 EBITDA Margin % is 112.40% as of Mar. 2026, which is 632% above its 10-year median of 15.36. GuruFocus rates GBCS with a GF Score™ of 45/100 and a GF Value™ of $2.14 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Selectis Health ranks better than 86.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Selectis Health's EBITDA for the
three
months ended in Mar. 2026 was $8.19 Mil. Selectis Health's Revenue for the
three
months ended in Mar. 2026 was $7.29 Mil. Therefore, Selectis Health's EBITDA margin for the quarter that ended in Mar. 2026 was 112.40%.
Selectis Health (OTCPK:GBCS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Selectis Health EBITDA Margin % Related Terms
Selectis Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Selectis Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GBCS vs AMS, BICX, NUMIF: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Selectis Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selectis Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Selectis Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Selectis Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selectis Health (GBCS) has a EBITDA Margin % of 112.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Selectis Health and its competitors. This is 632% above median its historical median of 15.36. According to the industry distribution chart, Selectis Health ranks #87 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 13%.
Is Selectis Health's EBITDA Margin % too high?
Selectis Health's current EBITDA Margin % of 112.40% is 632% above median its 10-year median of 15.36. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Selectis Health's value of 112.40% is 1000.9% above this industry median. Based on the distribution chart, Selectis Health ranks #87 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Selectis Health has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Selectis Health's EBITDA Margin % compare to AMS and BICX?
According to the Healthcare Providers & Services industry distribution chart, Selectis Health ranks #87 out of 668 companies for EBITDA Margin %. This places Selectis Health in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Selectis Health's value of 112.40% is 1000.9% above this benchmark. While the company's 10-year median is 15.36 vs. the industry median of 10.21, Selectis Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selectis Health's current EBITDA Margin % of 112.40% is 1000.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Selectis Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selectis Health's current EBITDA Margin % is 112.40%, which is 632% above median its own 10-year median of 15.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selectis Health stock overvalued right now?
Based on GuruFocus' analysis, Selectis Health (GBCS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.14, compared to a current price of $5.25 — trading 145.3% above its estimated fair value. The current EBITDA Margin % is 112.40%, which is 632% above median its 10-year median of 15.36 and 1000.9% above the Healthcare Providers & Services industry median of 10.21. Selectis Health's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Selectis Health (GBCS), the current EBITDA Margin % is 112.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selectis Health (GBCS) Overvalued in 2026?
Based on GuruFocus' analysis, Selectis Health stock appears to be overvalued.
The current stock price of $5.25 is trading 145.3% above its estimated GF Value™ of $2.14.
GuruFocus considers Selectis Health to be Significantly Overvalued.
Key valuation signals for GBCS:
EBITDA Margin %: 112.40% (632% above median its 10-year median of 15.36)
GF Value™: $2.14 vs. price of $5.25 (145.3% above fair value)
Industry Position: 1000.9% above the Healthcare Providers & Services median (#87 of 668)
No single metric tells the full story. See the GBCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selectis Health Inc owns and operates medical care facilities in the healthcare industry. The company acquires, develops, leases, and manages healthcare real estate and provides healthcare operations through its wholly-owned subsidiaries. The portfolio is comprised of investments in the following healthcare operations: (i) senior housing (including independent and assisted living) and (ii) post-acute/skilled nursing. It makes investments within the healthcare operations using the following six investment products: (i) direct ownership of properties, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management, (v) the Housing and Economic Recovery Act of 2008, which represents investments in senior housing operations, and (vi) owning healthcare operations.
45GF Score
Get the complete analysis for GBCS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GBCS has been successfully added to your 
